InsiderFinancial

$PETS Heading To New Highs

Long
NASDAQ:PETS   PetMed Express, Inc.
$PETS made a major breakout yesterday on heavy volume after a strong earnings beat. The $24 resistance level was broken through and we see the stock set to keep climbing. In looking at Q2 results, here are the highlights:

PetMed Express (NASDAQ:PETS): Q2 GAAP EPS of $0.33 beats by $0.07.

Revenue of $69.94M (-2.0% Y/Y) beats by $0.29M.

$PETS is also paying a quarterly dividend of $.27/share for a yield of 5.56%.

PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventative, flea and tick preventative, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, strollers, and other pet supplies. It sells its products through its Internet Website; telephone contact center; and direct mail/print through brochures and postcards. PetMed Express, Inc. was founded in 1996 and is headquartered in Delray Beach, Florida.

As always, trade with caution and use protective stops.

Good luck to all!

To receive our alerts via email and SMS, join Insider Financial for Free at signup.insiderfinancial.com

We are not financial advisors. Always conduct your own research and read our full disclaimer at insiderfinancial.com/disclaimer/
Clause de non-responsabilité

Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.